| Title: | Plasma proteomic profiles predict individual future health risk |
| Journal: | Nature Communications |
| Published: | 28 Nov 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38016990/ |
| DOI: | https://doi.org/10.1038/s41467-023-43575-7 |
| URL: | https://www.nature.com/articles/s41467-023-43575-7.pdf |
| Citations: | 20 (20 in last 2 years) as of 8 Aug 2024 |
Publication 8238
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Developing a single-domain assay to identify individuals at high risk of future events is a priority for multi-disease and mortality prevention. By training a neural network, we developed a disease/mortality-specific proteomic risk score (ProRS) based on 1461 Olink plasma proteins measured in 52,006 UK Biobank participants. This integrative score markedly stratified the risk for 45 common conditions, including infectious, hematological, endocrine, psychiatric, neurological, sensory, circulatory, respiratory, digestive, cutaneous, musculoskeletal, and genitourinary diseases, cancers, and mortality. The discriminations witnessed high accuracies achieved by ProRS for 10 endpoints (e.g., cancer, dementia, and death), with C-indexes exceeding 0.80. Notably, ProRS produced much better or equivalent predictive performance than established clinical indicators for almost all endpoints. Incorporating clinical predictors with ProRS enhanced predictive power for most endpoints, but this combination only exhibited limited improvement when compared to ProRS alone. Some proteins, e.g., GDF15, exhibited important discriminative values for various diseases. We also showed that the good discriminative performance observed could be largely translated into practical clinical utility. Taken together, proteomic profiles may serve as a replacement for complex laboratory tests or clinical measures to refine the comprehensive risk assessments of multiple diseases and mortalities simultaneously. Our models were internally validated in the UK Biobank; thus, further independent external validations are necessary to confirm our findings before application in clinical settings.</p>
8 Authors
- Jia You
- Yu Guo
- Yi Zhang
- Ju-Jiao Kang
- Lin-Bo Wang
- Jian-Feng Feng
- Wei Cheng
- Jin-Tai Yu
1 Application
| Application ID | Title |
|---|---|
| 19542 | Identifying multi-level biomarkers and disease mechanisms for major mental disorders |
Enabling scientific discoveries that improve human health